Elevation Oncology Inc (ELEV) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Elevation Oncology Inc (ELEV) has a cash flow conversion efficiency ratio of -0.272x as of March 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-12.71 Million) by net assets ($46.73 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Elevation Oncology Inc stock valuation for the company's overall valuation and market capitalisation.
Elevation Oncology Inc - Cash Flow Conversion Efficiency Trend (2019–2024)
This chart illustrates how Elevation Oncology Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Elevation Oncology Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Elevation Oncology Inc ranked by their cash flow conversion efficiency. See ELEV operating cash to total liabilities to evaluate how effectively operating cash flow covers total debt obligations.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
APPIA RARE EARTH+U O.N.
F:A0I0
|
-0.002x |
|
Blossom M&C Co. Ltd
KQ:263920
|
-0.023x |
|
Signet Industries Limited
NSE:SIGIND
|
0.043x |
|
Wenzhou Kangning Hospital Co. Ltd
F:4WK
|
0.060x |
|
DAP Corporation
KQ:066900
|
-0.045x |
|
Point Mobile Co. Ltd
KQ:318020
|
0.135x |
|
TMK Energy Ltd
AU:TMK
|
-0.030x |
|
Hermana Holding ASA
OL:HERMA
|
-0.040x |
Annual Cash Flow Conversion Efficiency for Elevation Oncology Inc (2019–2024)
The table below shows the annual cash flow conversion efficiency of Elevation Oncology Inc from 2019 to 2024. View Elevation Oncology Inc stock quote for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $60.02 Million | $-36.36 Million | -0.606x | +40.90% |
| 2023-12-31 | $54.81 Million | $-56.18 Million | -1.025x | +41.21% |
| 2022-12-31 | $49.03 Million | $-85.48 Million | -1.743x | -713.12% |
| 2021-12-31 | $140.70 Million | $-30.17 Million | -0.214x | -140.24% |
| 2020-12-31 | $-23.08 Million | $-12.30 Million | 0.533x | -42.58% |
| 2019-12-31 | $-5.87 Million | $-5.45 Million | 0.928x | -- |
About Elevation Oncology Inc
Elevation Oncology, Inc., an oncology company, focuses on the discovery and development of cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs. It's lead candidate is EO-3021, an antibody-drug conjugate (ADC) comprised of a fully human anti-Claudin 18.2 immunoglobulin G1 monoclonal antibody (mAb) site-specifically conjugated with a cleavable link… Read more